Diane Simeone

Jun 28, 2024 | nature.com | Linda Bojmar |Constantinos P. Zambirinis |Junbum Kim |Ankur Choubey |Jose Jessurun |Hakon Blomstrand | +21 more

AbstractMetastasis occurs frequently after resection of pancreatic cancer (PaC). In this study, we hypothesized that multi-parametric analysis of pre-metastatic liver biopsies would classify patients according to their metastatic risk, timing and organ site.

Feb 26, 2024 | cancernetwork.com | Diane Simeone

Starting April 1, 2024, Diane M. Simeone, MD will start her new position as director of the University of California San Diego (UCSD) Health Moores Cancer Center.1In a conversation with CancerNetwork®, Simeone highlighted her excitement to be working with an institution that she said aligns with her goals and values. During her time as director, she said that she wants to focus more on early detection of pancreatic cancer, which may help save many patients.

Jan 31, 2024 | cancernetwork.com | Rina Lokaj |Diane Simeone

Diane M. Simeone, MD, has been appointed director of the University of California San Diego (UCSD) Health Moores Cancer Center. Her new position will go into effect April 1, 2024.1In an interview with CancerNetwork®, Simeone described her excitement for this new path in her career. As an expert in pancreatic surgery as well as surgical oncology, her ambitions within this position include expanding the center’s clinical trial goals and increasing early detection of pancreatic cancer.

Apr 25, 2023 | onclive.com | Diane Simeone

Diane M. Simeone, MD, Laura and Isaac Perlmutter Professor of Surgery, Department of Surgery, professor, Department of Pathology, NYU Grossman School of Medicine, director, the Pancreatic Cancer Center, associate director, Translational Research, the Perlmutter Cancer Center, discusses the phase 1/2 EVEREST-1 trial (NCT05736731) evaluating the autologous CAR T-cell therapy A2B530 in patients with solid tumors.

Apr 25, 2023 | onclive.com | Diane Simeone

Diane M. Simeone, MD, Laura and Isaac Perlmutter Professor of Surgery, Department of Surgery, professor, Department of Pathology, NYU Grossman School of Medicine, director, the Pancreatic Cancer Center, associate director, Translational Research, the Perlmutter Cancer Center, discusses the phase 1/2 EVEREST-1 trial (NCT05736731) evaluating the autologous CAR T-cell therapy A2B530 in patients with solid tumors.